Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 October 2023 | Story Samkelo Fetile | Photo Stephen Collett
Public Management Memorial Lecture
From left; Prof Philippe Burger, Prof Francis Petersen, Premier Mxolisi Dukwana, and Dr Mareve Biljohn.

The University of the Free State (UFS), Department of Public Administration and Management recently hosted its Public Management Memorial Lecture, which was delivered by the Honourable Mxolisi Dukwana, the Premier of the Free State. This year's Public Management Memorial Lecture, titled 'Public Administration and Management as a Method and Tool of Delivering an Ethical, Capable, and Developmental State,' delved into crucial aspects of governance.

In his welcoming address, Prof Francis Petersen, Vice-Chancellor and Principal of the UFS, provided insight into the university's Vision 130 and the university’s strategy, emphasising values such as accountability, social justice, and care. The university’s commitment to engaging on matters of public significance was also highlighted.

Fostering collaboration

Prof Petersen emphasised the importance of collaboration and co-creation – particularly in the post-COVID-19 era – to achieve optimal outputs and outcomes. “The Public Management Memorial Lecture aims to foster collaboration between academia, students, and practitioners in the field of public administration and management.”

In his introduction of Premier Dukwana, Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences, highlighted Dukwana's role in various government positions, including as the ANC provincial treasurer and, more recently, as the Premier of the Free State.

Addressing challenges and opportunities

In his address, Premier Dukwana acknowledged the need for a collective effort to ensure an ethical, capable, and developmental state, emphasising the challenges faced in the current socio-political landscape. Premier Dukwana acknowledged the need for introspection regarding the state's foundations, values, and mechanisms of service delivery. “Understandably, this is quite an involved and extensive subject that interrogates not only the ethical and capable attributes of the democratic state, but also whether the democratic state is itself developing and evolving towards a horizon that is developmental in outlook.” He stressed the importance of upholding constitutional values and principles, accentuating the need for accountability, transparency, and adherence to the Batho Pele principles.

Premier Dukwana outlined key interventions in the Medium-Term Strategic Framework (MTSF), emphasising the need for a capable and honest government, improved leadership, good governance, and accountability. He called for modernised business processes, improved financial management capability, and participatory local governance mechanisms.

The importance of a social compact was also highlighted, as well as the need to set aside narrow interests for the common goal of long-term growth and development. He stressed the need for a vibrant civil society and underscored the role of public servants in effecting positive change in service delivery.

Reducing bureaucratic red tape

The Premier concluded his address by emphasising the importance of reducing bureaucratic red tape and initiating programmes to streamline service delivery. He expressed optimism for further collaboration with the UFS in strengthening governance and public administration practices. “I am looking forward to having further discussions with the UFS as it relates to the MOU between the UFS and the Free State Provincial Government. The UFS can play a crucial role in helping us to strengthen governance, and specifically improve on public administration and management approaches and practices with the aim of accelerated and improved service delivery.”

The Public Management Memorial Lecture served as a platform for robust discussions on the challenges and opportunities in public administration and management. Premier Dukwana's insights underscored the imperative for ethical, capable, and developmental governance, setting the stage for continued collaboration and engagement on these critical issues.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept